C-Src confers resistance to mitotic stress through inhibition DMAP1/Bub3 complex formation in pancreatic cancer
Chromatin modification at mitosis is closely related to transcriptional reactivation in the subsequent cell cycle. We reasoned this process is deregulated by oncogenic signals, which would contribute to mitotic stress resistance in pancreatic cancer. Here, we show DMAP1/Bub3 complex mediates mitotic stress-induced cellular apoptosis, while this effect is counteracted by c-Src in pancreatic cancer cells. Our study aims to uncover an unidentified mechanism underlying the distinct response to mitotic stress between normal cells and pancreatic cancer cells.
The interaction between Bub3 and DMAP1 upon mitotic stress signaling was determined through molecular and cell biological methods. The inhibitory effect of c-Src on DMAP1/Bub3-mediated DNA methylation and gene transcription profile was investigated. The association between c-Src-mediated DMAP1 phosphorylation and paclitaxel activity in vivo and clinicopathologic characteristics were analyzed.
Mitotic arrest induced p38-dependent phosphorylation of Bub3 at Ser211, which promotes DMAP1/Bub3 interaction. DMAP1/Bub3 complex is recruited by TAp73 to the promoter of anti-apoptotic gene BCL2L1, thus mediates the DNA methylation and represses gene transcription linked to cell apoptosis. Meanwhile, DMAP1 was highly phosphorylated at Tyr 246 by c-Src in pancreatic cancer cells, which impedes DMAP1/Bub3 interaction and the relevant cellular activites. Blocking DMAP1 pTyr-246 potentiates paclitaxel-inhibited tumor growth. Clinically, DMAP1 Tyr 246 phosphorylation correlates with c-Src activity in human pancreatic cancer specimens and poor prognosis in pancreatic cancer patients.
Our findings reveal a regulatory role of Bub3 in DMAP1-mediated DNA methylation upon mitotic stress and provide the relevance of DMAP1 pTyr-246 to mitotic stress resistance during pancreatic cancer treatment.
DNA methytransferase 1 associated protein
DNA methytransferase 1 (DNMT1)
Human normal pancreatic duct epithelial
Spindle assembly checkpoint
During Mitosis, the duplicated chromosomes are separated into two daughter cells and its accuracy is critical for guaranteeing the integrity of genetic information . The checkpoint responsible for the fidelity of chromosome segregation is termed spindle assembly checkpoint (also known as the mitotic checkpoint), which prevents chromosomes separation until each chromosome is correctly attached to the spindle apparatus. Mis-attachment of spindle to kinetchore leads to mitotic arrest resulted from mitotic checkpoint activation [2, 3]; and prolonged mitotic arrest accordingly initiates responsive signals that impede cell proliferation and survival, which avoids accumulation of cells with aneuploidy [4, 5]. Currently, the antimitotic agents such as paclitaxel, a microtubule-stabilizing drug which can result in mitotic arrest and apoptotic cell death, have been broadly utilized during the clinical cancer treatment . Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal diseases with approximately 6 months of median survival . Up to now, the clinical regimens proven to increase survival for patients with advanced metastatic PDAC include standard gemcitabine and gemcitabine-based therapies . Previous studies and clinical trials demonstrate that administration of paclitaxel in combination with gemcitabine shows a survival benefit over gemcitabine alone in advanced PDAC. However, a major conundrum for the clinical PDAC treatment is its innate resistance to available chemotherapies . Clinical data indicates although effective clinical responses to antimitotic agents initially, a significant proportion of patients eventually develop resistance to the treatment . This issue causes a large number of studies which aim to uncover mechanisms underlying the drug resistance, and multiple related cellular targets have been identified in a context dependent manner [11, 12, 13, 14, 15]. Further investigation in this regard would be important for a better understanding of how cancer cells escape unbeneficial effects from mitotic arrest and improving the relevant clinical therapy.
Epigenetic state of chromatin is closely related to mitosis progression [16, 17, 18, 19]. Although transcription activity in mitosis is entirely silenced, the altered profile of epigenetic modifications at mitosis can exhibit their impacts on the transcriptional reactivation in the subsequent cell cycle [20, 21, 22, 23]. Given this, it could be inferred that epigenetic regulation at mitosis under mitotic arrest would be involved in the modulation of genes transcription and relevant cellular activities postmitosis. In this regard, the distinct response to mitotic arrest between normal cell and cancer cell might accordingly produce different physiological outcomes.
Bub3 belongs to spindle assembly checkpoint (SAC) components which forms complex with Bub1 to mediate inhibitory effect on the ubiquitin ligase activity of the anaphase-promoting complex/cyclosome (APC/C) and the proteasome-mediated destruction of securin and cyclin B in mitosis [2, 24]. In contrast with the general mechanism, previous studies have revealed that the involvement of Bub3 in SAC can be regulated in a manner specific for cancer cells [25, 26]. Besides the canonical implication in SAC, Bub3 also potentially participates into other cellular activities including the regulation of DNA damage response and gene transcription [27, 28, 29]. In addition, Bub3 is found to interact with non-SAC protein, among which TAp73,a transcriptional factor, is well investigated and shown to importantly regulate SAC protein localization and activities [30, 31]. TAp73 belongs to p53 family and is characterized by its pro-apoptotic activities similar to those of p53, in contrast with the anti-apoptotic function of the ΔNp73 subfamily (lacking the TA domain) . Thus, it would be interesting to study whether Bub3 is involved in the regulation of transcriptional activity of TAp73 and the relevant physiological function.
DMAP1 was initially identified as a protein associated with the N-terminal domain of DNA methytransferase 1 (DNMT1), the major enzyme that mediates mammalian DNA methylation [33, 34]. DMAP1/DNMT complex importantly contributes to transcriptional repression via the maintenance of methyl-CpG, in which a series of functional components such like transcriptional co-repressor TSG101, histone deacetylases (HDACs) are involved . With respect to cell cycle progression, the effect of DMAP1 on transcriptional activity has been linked to G1/S and G2/M transition [36, 37]; while the regulation of DNA methylation by DMAP1 in mitosis and its potential to transcriptional reactivation postmitosis remains elusive.
Here, we found p38-dependent Bub3 phosphorylation promotes its binding to DMAP1 under mitotic arrest. Through interaction with TAp73, Bub3/DMAP1 potentiates DNMT1-mediated DNA methylation at the promoter region of anti-apoptotic genes, which blocks gene transcription post mitosis and leads to increased cellular apoptosis. In pancreatic cancer cells, DMAP1 is highly phosphorylated by c-Src; this phosphorylation abrogates DMAP1/Bub3 complex formation under mitotic arrest and eventually maintains cell survival.
Materials and methods
Antibodies that recognize DMAP1, Src, phosphor-Src pY416, CyclinB1, CyclinD1 was obtained from Cell Signaling Technology. Antibodies that recognize Flag, HA, actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Sigma. Antibody against Bub3 was obtained from Santa Cruz Biotechnology. Antibody against TAp73 antibody was from Millipore. Rabbit polyclonal Bub3 pSer-211 and DMAP1 pTyr-246 antibody was made by Signalway Antibody.
A peptide containing Bub3 pSer-211 or DMAP1 pTyr-246 was injected into rabbits. The rabbit serum was collected and purified using an affinity column with non-phosphorylated Bub3 Ser-211 or DMAP1 Tyr-246 peptides to exclude the antibodies for non-phosphorylated Bub3 or DMAP1, followed by an affinity column with phosphorylated Bub3 Ser-211 or DMAP1 Tyr-246 peptides to bind to and purify the Bub3 pSer-211 or DMAP1 pTyr-246 antibody. The Bub3 pSer-211 and DMAP1 pTyr-246 antibodies were then eluted and concentrated. Thymidine and Nocodazole were purchased from Sigma. Glutathione SepharoseTM 4B was obtained from GE Healthcare. FITC-AnnexinV apoptosis kit was from BD.
Pancreatic cancer cell line PANC-1 was grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS; SW1990 cells were maintained in PRMI-1640 plus 10% FBS. Immortal human pancreatic ductal epithelial cell line HPDE was cultured in DMEM supplemented with 10% FBS.
DNA constructs and mutagenesis
The DNA constructs and mutagenesis were described as previously (41). pLKO.1 human DMAP1 shRNA was generated with the oligonucleotide CCGGATCAGCAAGAAGGACATTATCCTCGAGGATAATGTCCTTCTTGCTGATTTTTTG (Sigma). pLKO.1 human TAp73 shRNA was generated with the oligonucleotide CCGGCCAAGGGTTACAGAGCATTTACTCGAGTAAATGCTCTGTAACCCTTGGTTTTTG (Sigma). The pcDNA3.1-DMAP1-Flag was obtained from Changsha You Bao Biotechnology Co. Ltd. (Changsha, China). DNA sequences encoding Bub3 and DMAP1 were inserted into the pcDNA3.1 vector and Flag or HA tag was fused to the N terminus.
HPDE, PANC-1 and SW1990 cells were transfected with various plasmids using lipofectamine 2000 (Invitrogen) according to the vendor’s instructions.
For mitotic arrest, cells were first synchronized by thymidine double block (2 mM) for indicated length of time. Nocodazole was then added (200 nM) for 16 h. Mitotic cells were then harvested by gentle pipetting.
Immunoprecipitaion and immunoblotting
Immunoprecipitaion and immunoblotting were performed as described previously(41). Briefly, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS and cocktails of proteinase and phosphatase inhibitors). For exogenous immunoprecipitation, cell lysates were centrifuged to remove the cell debris and incubated in flag-M2 beads (Sigma) at 4 °C overnight. The beads were boiled after extensive washing. The proteins were eluted with SDS-PAGE sample buffer, resolved via SDS polyacrylamide gels and transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% BSA, incubated with indicated specific primary antibodies and exposed to horseradish peroxidase (HRP)-conjugated secondary antibody (Sigma). The chemiluminescence signals emanating from the membranes were detected by ECL reagent. For endogenous immunoprecipitation, cells were lysed in lysis buffer and incubated with indicated antibodies at 4 °C overnight. The immunoprecipitates were incubated with protein A/G agarose beads (Santa Cruz) for 2–3 h followed by five washes.
Mass spectrometric analysis
Bub3-associated proteins under mitotic arrest were analyzed by LC-MS/MS as described previously(41). Briefly, Flag-Bub3 associated proteins from the immune-precipitation assay were acetone-precipitated in vitro at − 20 °C overnight and resuspended in 50 mM ammonium bicarbonate buffer containing Rapigest (Waters Corp). The sample was heated to 95 °C for 10 min and allowed to cool down before 100 ng of sequencing-grade modified trypsin (Promega) was added. The digestion proceeded overnight at 37 °C and was analysed by LC-MS/MS using an Orbitrap-Elite mass spectrometer (Thermo Fisher Scientific). Proteins were identified by comparing the fragment spectra against those in the SwissProt protein database (EBI) using Mascot v.2.3 (Matrix Science) and Sequest v.1.20 via Proteome Discoverer v.1.3 (Thermo Fisher Scientific) software.
Microarray profiling analysis
Total mRNA was purified from cells expressing wildtype DMAP1 and Y246F mutant DMAP1. Expression profiling analysis was performed using Affymetrix U133A microchips.
Gene expression analysis
Total RNA was isolated from cells using RNAzol RT (Molecular Research Center) following the manufacturer’s instructions. We synthesized cDNA from 1 μg total RNA using iScript cDNA synthesis kit (Bio-Rad) and quantified mRNA levels by Real-time PCR using SYBR Green (Bio-Rad). We ran samples in technical triplicates and calculated relative mRNA levels normalized to actin mRNA levels in the same samples. Primers for HMGA2 were: 5’ACTTCAGCCCAGGGACAAC 3′ (forward) and 5’ CACAATAGCGAAAGTCCGAGG 3′ (reverse). Primers for BCL2L1were: 5’ CCAGAAGGGACTGAATCGGAG 3 ‘(forward) and 5’CGTCTCCAACAATCACCCAACAC 3′(reverse).
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was conducted using the Chromatin immunoprecipitation kit (Millipore) according to the manufacturer’s guidelines. In brief, cells were sonicated on ice. The supernatant was incubated with IgG or indicated antibodies at 4 °C. Genomic DNA in immune complexes was extracted and prepared for PCR reactions. Quantitative real-time PCR was used to measure the amount of bound DNA, and the value of enrichment was calculated according to the relative amount of input and the ratio to IgG. The primers covering TAp73 binding site of human BCL2L1 were: 5’CACGCCTGTAAACGATTCTCC3′ (forward) and 5’GCAGACTCGCTTACAGGAGAATC 3’ (reverse). Control primers selected against a specific region of chromosome 12 were 5’ATGGTTGCCACTGGGGATCT3’ (forward) and 5’TGCCAAAGCCTAGGGGAAGA3’(reverse).
Pyrosequencing methylation analysis
Bisulphite treatment of 2 μg of genome DNA was undertaken using the EZ DNA Methylation Kit™ (Zymo Research). Hot-start PCR was carried out with HotStar Taq® Master Mix Kit (Qiagen Ltd.) using 3 μl bisulphite treated DNA. The targeted CpGs (BCL2L1 promoter CpG island) were selected and Pyrosequencing was carried out using the PyroMark Q96 ID (QIAGEN) system according to manufacturer’s protocol. The methylation status was automatically analyzed by Pyro Q-CpG software. Primers against the sequence included in BCL2L1 promoter region were:5’ATATATTGTGTGGTTTAGGGTGTAA3’(forward),5’biotin-AAAACCAACCTAACCAATATAATAAAACCC3’(reverse), and AGTAGTTGGGATTATAGG.
Whole-genome bisulphate sequencing (WGBS) analysis
Genomic DNA from SW1990 cells expressing indicated plasmids was extracted using the Masterpure DNA Purification kit (Epicentre). For normal BS-seq library constructing, genomic DNA was fragmented to an average size of 350 bp using a Covaris S2 sonicator. Bisulfite sequencing libraries were constructed using the Illumina TruSeq DNA Library Preparation kit protocol. Following fragmentation, libraries were constructed using the Illumina Paired-End protocol consisting of end repair, “A” base addition and methylated-adaptor ligation. Ligated DNA was bisulfite converted using the EZ DNA Methylation-Gold kit (ZYMO). Final libraries were run on the 2100 Bioanalyzer (Agilent) using the High-Sensitivity DNA assay for quality control purposes. To achieve > 10× genome coverage, libraries were quan¬tified by qPCR with the Library Quantification kit for Illumina sequencing platforms (KK4824, Kapa Biosystems), using the 7900HT Real-Time PCR System (Applied Biosystems), and sequenced on the Illumina HiSeq 2000. The sequences alignment and methylation calling were performed with version 2.43 of BSMAP software.
Recombinant protein purification
WT and mutant GST-Bub3, His-Bub3 and GST-DMAP1 were expressed in bacteria and purified, as described previously(41).
In vitro kinase assay
Bacterially purified recombinant WT and mutant His-Bub3 was incubated with His-p38 in kinase assay buffer supplemented with 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 50 mM MgCl2, 1 mM Na3VO4, 1 mM dithiothreitol (DTT), 5% glycerol, 0.2 mM ATP, 10 μCi of [γ − 32P]ATP) at 25 °C for 1 h. After the reaction, p38 was removed by extensive washing with RIPA buffer and kinase assay buffer. Purified recombinant WT and mutant GST-DMAP1 was incubated with His-c-Src in kinase assay buffer supplemented with 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 50 mM MnCl2, 1 mM Na3VO4, 1 mM dithiothreitol (DTT), 5% glycerol, 0.2 mM ATP, 10 μCi of [γ − 32P]ATP) at 25 °C for 1 h.The His-Bub3 bound beads were recovered by centrifugation. For kinase phosphorylation analyses, the His-Bub3 bound beads were subjected to SDS-PAGE, and then autoradiography after incubation with EN3HANCE (PerkinElmer). The GST-Bub3 bound beads after p38 treatment in absence of hot ATP were further incubate with GST-DMAP1 for protein interaction assay as indicated.
Apoptosis assay was performed as instructed by the manufacturer (BD). Cells were resuspended in binding buffer containing FITC-conjugated Annexin V and PI. Cell apoptosis was detected by a flow cytometer (BD).
Cell cycle analysis
Cells were fixed in 70% ice-cold ethanol at − 20 °C for 24 h. After several washes, fixed cells were resuspened in PBS containing RNase and PI solution and incubated at 37 °C for 30 min in darkness. Cell cycle distribution was analyzed by a flow cytometer (BD).
Six-week-old male nu/nu mice were subcutaneously injected with 5 × 106 SW1990 cells in a volume of 150 μl of PBS/Matrigel (1/1 (v/v)). Primary tumour size was measured by a digital caliper. All animal experiments conformed to the guidelines of the Institutional Animal Care and Use Committee of Shanghai Jiaotong University.
Ninety pairs of human PDAC tissues and their matched adjacent-tumour samples were collected from patients who had undergone a pancreatectomy at the Shanghai General Hospital. All samples used in this research were obtained with written informed consent from patients. The use of human tissues was approved by the Institutional Ethics Board of Shanghai General Hospital and conforms to the Helsinki Declaration and to local legislation. Immunohistochemistry was performed on paraffin-embedded sections of human pancreata (90 pancreatic cancer tissues). Human pancreatic cancer tissue sections (3–5 μm) were deparaffinized and rehydrated. Antigen retrieval was performed by boiling tissue sections in 10 mM citrate buffer (pH 6.0) in a microwave oven for 30 min. The activity of endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 min at room temperature. After washing, non-specific binding sites were blocked by incubating the slides with 10% FBS/PBS for 30 min at room temperature. Sections were subsequently incubated with rabbit polyclonal anti-DMAP1 pTyr-246 (Signalway, 1:50) at 4 °C overnight. After incubation with the primary antibody, the sections were washed and incubated with secondary antibodies and DAB staining reagent with GTVisionTM Detection System/Mo&Rb Kit according to manufacturer’s instructions. After counterstain with hematoxylin and dehydration, the sections were mounted and imaged using the Leica microscope. Immunoreactivity was semi-quantitatively evaluated according to intensity and area: the staining intensity of pancreatic cancer cells themselves was recorded as “weak (0–2)” or “strong staining (2.1-5)”. Statistical analysis of the survival time for 90 patients with low vs moderate or high DMAP1 pTyr-246 level, was performed using the GraphPad Prism 5 Software. The Kaplan-Meier method and log-rank tests were used for survival analysis. Statistical significance was set at p < 0.05. The cox multivariate analysis with patient sex and age was performed with SPSS 19 Software.
Statistical analysis was conducted with the two-tailed unpaired Student’s t-test. All data represent the mean ± s.e.m. of three independent experiments.
Bub3 interacts with DMAP1 during mitotic arrest
Subsequently, Bub3/DMAP1 interaction was examined in pancreatic cancer cell PANC-1 cells and SW1990 cells (Additional file 1: Figure S1G). Unexpectedly, mitotic arrest only led to a slight increase of DMAP1/Bub3 interaction in cancer cells (Fig. 1d), implying certain cancer-specific signaling participate in the regulation of Bub3/DMAP1 complex formation. The hyperactive c-Src signaling has been implicated in pancreatic cancer development [38, 39]. PANC-1 and SW1990 cells were treated with c-Src inhibitor SU6656 that did not show significant effect on mitotic index (Additional file 1: Figure S1H). As a result, c-Src inhibition (the reduced Y416 phosphorylation level) evidently enhanced induced Bub3/DMAP1 complex formation (Fig. 1d) under mitotic arrest, suggesting c-Src plays a negative role in Bub3/DMAP1 interaction. To support this finding, we expressed a constitutively active c-Src (c-Src Y527F) in HPDE cells and found c-Src Y527F largely blocked mitotic arrest-induced DMAP1/Bub3 interaction (Fig. 1e). To further characterize DMAP1-binding region of Bub3, we constructed series truncates of Bub3 spanning various amino acids sequence (Fig. 1f). Co-immunoprecipitation analyses in mitotic-arrested HPDE cells indicated the Bub3 truncates with deletion of 197-306aa (amino acid) or 203-328aa instead of 1-97aa or 98-196aa lost the ability of DMAP1binding, revealing DMAP1-binding region of Bub3 is located in the amino acid sequence between 203aa and 306aa (Fig. 1f, right panel).
p38 phosphorylates Bub3 at Ser211 and promotes Bub3/DMAP1interaction
C-Src phosphorylates DMAP1 at Tyr246 and disrupts Bub3/DMAP1 complex formation
C-Src phosphorylates DMAP1 and blocks Bub3/DMAP1-repressed anti-apoptotic genes transcription
C-Src-mediated DMAP1 phosphorylation blocks Bub3/DMAP1-mediated DNA methylation
Bub3 was associated with the transcriptional factor TAp73 during mitotic arrest (Additional file 1: Figure S1C), and the co-immunoprecipitation analysis showed this interaction was independent on Bub3 S211 phosphorylation (Additional file 5: Figure S5F). We wondered whether TAp73 was involved in the transcriptional regulation by Bub3/DMAP1 complex. As shown in Fig. 5d, TAp73 depletion reversed BCL2L1 transcription in SW1990 cells expressed with DMAP1 Y246F, suggesting TAp73 is critical for transcription suppression mediated by DMAP1/Bub3. Sequence analysis revealed ‘ggcatgcgccaccacgcc’ at BCL2L1 promoter are putative TAp73 binding sites and ChIP analyses indicated TAp73 was enriched at the promoter region covering the binding sites at mitosis (Fig. 5e). Additionally, BCL2L1 promoter-associated Bub3 (Fig. 5f, left panel and Additional file 5: Figure S5G), Bub3 S211 phosphorylation (Fig. 5f, right panel) were also found to be significantly increased under mitotic arrest in SW1990 cells, which were blocked by TAp73 depletion. Similarly, mitotic arrest dramatically promoted the accumulation of DMAP1 (Fig. 5g) as well as DMNT1 (Additional file 5: Figure S5H) at BCL2L1 promoter regions in SW1990 cells expressed with DMAP1 Y246F but not DMAP1 Y246F/Bub3 S211A, in comparison with the WT counterparts. In contrast, DMAP1 Y246 phosphorylation was failed to be detected at promoter sites during mitotic arrest (Additional file 5: Figure S5I). These data suggest TAp73 is responsible for the accumulation of Bub3 and DMAP1 complex at promoter, in which Bub3 S211 phosphorylation is indispensable for DMAP1/DNMT1 recruitment.
DMAP1 Y246 phosphorylation counteracts antitumor activity of paclitaxel in vivo
DMAP1 Y246 phosphorylation correlates prognosis in human tumour specimens
We demonstrated DMAP1 Y246 phosphorylation blocked Bub3-mediated transcriptional repression. To further define the clinical relevance of our finding, we first examined the c-Src activity and DMAP1 pY246 by immunoblotting of tissue extracts from 8 human pancreas tumour specimens. As a result, DMAP1 pY246 levels (Fig. 6c) were generally increased along with elevated c-Src/c-Src pY416 levels (Additional file 6: Figure S6C) in tumour tissues compared with the normal counterparts. In addition, IHC analyses were performed to examine DMAP1 pY246 levels in serial sections of 90 human pancreas tumour specimens (Fig. 6d). The specificity of antibody against DMAP1 Y246 phosphorylation was validated by using IHC analyses with specific blocking peptides (Additional file 6: Figure S6D). Survival duration of patients was evaluated with respect to low (0–2 staining) versus high (2.1–5 staining) level of DMAP1 Y246 phosphorylation (Fig. 6e and Additional file 6: Figure S6E). Patients whose tumours had low DMAP1 pY246 levels (29 cases) had a median survival that was not reached; those whose tumours had high DMAP1 pY246 levels (61 cases) had significantly lower median survival duration of 10.5 months. In a Cox multivariate model, the IHC scores of DMAP1 Y246 phosphorylation is an independent predictor of pancreatic cancer patient survival after adjusting for the age of the patient. These results reveal a tight relationship between DMAP1 Y246 phosphorylation and poor prognosis of human pancreatic cancer patient.
As the spindle checkpoint protein, Bub3 is responsible for the accurate chromosome segregation mainly through its inhibitory effect on APC/C-mediated ubiquitination prior to anaphase onset . Besides spindle checkpoint components, Bub3 is also found to interact with proteins related to other cellular activities including DNA damage and gene transcription [27, 28, 29], revealing the multifaceted function of Bub3. In the present study, we found mitotic arrest induces Bub3 pS211 by p38, which leads to its binding to DMAP1. The association of Bub3 with TAp73 further promotes the recruitment of Bub3/DMAP1 complex to promoter of TAp73-targeted anti-apoptotic genes, where DMAP1 associates with DMNT1 and presumably eventually mediates DNA methylation that results in repression of gene reactivation following mitosis (Fig. 6f). In addition to its canonical function, these findings demonstrate a crucial role of Bub3 in the regulation of DNA methylation and subsequent gene transcription in response to mitotic stress. Particularly, our study indicates Bub3 S211 phosphorylation mediated by p38 activation is restricted on the condition of mitosis arrest but not TGF-β stimulation at interphase (Additional file 2: Figure S2F and 2G), which is consistent with the result that p38/Bub3 interaction is exclusively detected at mitosis (Fig. 2c). This suggests Bub3/DMAP1/DNMT1 axis is operated as a specific signaling feedback upon mitotic stress. Of note, although our data shows Bub3/TAp73 complex formation is responsible for initiation of DMAP1/Bub3-DNMT1 signaling, the mechanism of how Bub3 interacts with TAp73 remains to be further investigated.
Mitotic defect leads to growth arrest and the failure of its correction can cause cell death, which is considered as a negative selection to prevent the occurrence of aneuploidy [4, 5]. Frequently, cancer cells are able to escape from detrimental effects resulted by mitosis dysregulation and thus are prone to aneuploidy occurrence [41, 42, 43], revealing there exists according aberrant signals that enable cancer cells to counteract the relevant stress signals. In our study, we found pancreatic cancer cells display high level of DMAP1 pY246 mediated by c-Src; and this blocks mitotic arrest-induced Bub3/DMAP1 interaction and thus protects cancer cells from mitotic arrest-induced apoptosis. Hyperaction of c-Src has been importantly implicated in pancreatic cancer progression , the positive impacts of c-Src-mediated DMAP1 pY246 on tumour growth exemplifies that the adaption of cancer cells to mitotic defect-induced stress is addicted to strong c-Src activity. Moreover, since our study shows p38 activity and Bub3 pS211 are basally presented at a notable level in cancer cells, it could be assumed that adequate c-Src activity is required for cancer cells to counteract p38/Bub3/DMAP1-induced apoptosis not only under mitotic arrest induced artificially but also at routine process of mitosis progression. Indeed, this is supported by clinical analysis showing that the level of DMAP1 pY246 generally correlates to poor prognosis of pancreatic cancer patient. Regulation of epigenetic modifications at mitosis is linked to transcriptional reactivation in the subsequent cell cycle [20, 21, 22]. In consistence to this, our data indicates DMAP1 pY246 facilitates transcription of antiapoptotic-gene BCL2L1 under mitotic arrest in cancer cells, which is linked to its negative effects on Bub3 pS211-mediated DNA methylation at BCL2L1promoter (Fig. 5). As it cannot be excluded that DMAP1 pY246 would be involved in other cellular events in addition to DMAP1-Bub3 interaction, the precise effects of DMAP1 pY246 on Bub3-mediated DNA methylation needs to be further clarified.
The identification of the novel role of Bub3 in gene reactivation following mitotic arrest uncovers a flexible and instrumental insight into how epigenetic modifiers are constantly regulated in response to environmental signals. On the other hand, the inhibitory effect of c-Src on Bub3/DMAP1/DNMT1 axis illustrates a critical way for cancer cells to resist mitotic stress, and this finding importantly provides a molecular basis for improving the therapy of pancreatic cancer that are refractory to anti-mitosis treatment with upregulated c-Src activity.
Our findings reveal Bub3/DMAP1 complex is crucial for responsive gene expression following mitotic arrest and demonstrate the survival advantage of cancer cells under mitotic stress is addicted to the inhibitory effect of c-Src on Bub3/DMAP1-mediated apoptosis.
We thank Liao.-Lu. Jian at East China Normal University for the technical support at Mass spectrometry analysis. This work was supported by the National Nature Science Foundation of China 81773006 (Y.J.), China Ministry of Science and Technology, National Key research and development program 2017YFA0506200 (Y.J.), National Nature Science Foundation of China 81372643 (X.W). National Nature Science Foundation of China 81702328 (J.L.).
This work was supported by the National Nature Science Foundation of China 81773006 (Y.J.), China Ministry of Science and Technology, National Key research and development program 2017YFA0506200 (Y.J.), National Nature Science Foundation of China 81372643 (X.W). National Nature Science Foundation of China 81702328 (J.L.).
Availability of data and materials
The datasets for microarray and WGBS analysis during the present study and other datasets analyzed during the present study are available from the corresponding author on reasonable request.
This study was conceived by YJ; YJ and JL designed the study; JL and BH performed the experiments; YJ, JL, BH, TW, and QZ analyzed and interpreted the data; WH, CM, YT, LZ, QY, and TZ reviewed the manuscript; YJ wrote the paper with comments from all authors. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All animal experiments conformed to the guidelines of the Institutional Animal Care and Use Committee of Shanghai Jiaotong University. The use of human tissues was approved by the Institutional Ethics Board of Shanghai General Hospital and conforms to the Helsinki Declaration and to local legislation.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 13.Dong G, Chen W, Wang X, Yang X, Xu T, Wang P, Zhang W, Rao Y, Miao C, Sheng C. Small molecule inhibitors simultaneously targeting Cancer metabolism and epigenetics: discovery of novel nicotinamide Phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors. J Med Chem. 2017;60:7965–83.PubMedGoogle Scholar
- 27.Derive N, Landmann C, Montembault E, Claverie MC, Pierre-Elies P, Goutte-Gattat D, Founounou N, McCusker D, Royou A. Bub3-BubR1-dependent sequestration of Cdc20Fizzy at DNA breaks facilitates the correct segregation of broken chromosomes. J Cell Biol. 2015;211:517–32.PubMedPubMedCentralGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.